{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T11:58:35Z","timestamp":1698580715502},"reference-count":7,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,2,7]],"date-time":"2006-02-07T00:00:00Z","timestamp":1139270400000},"content-version":"vor","delay-in-days":5030,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biopharm & Drug Disp"],"published-print":{"date-parts":[[1992,5]]},"abstract":"Abstract<\/jats:title>The absorption and disposition of fluvastatin have been studied in the female rabbit. In naive rabbits receiving a single oral dose (1 mg kg\u22121<\/jats:sup>) of [3<\/jats:sup>H] fluvastatin, absorption was rapid and amounted to c<\/jats:italic>. 90 per cent compared with an intravenous reference dose. The drug was subject to considerable first\u2010pass effect, its absolute bioavailability being 46 per cent. The steady\u2010state volume of distribution of fluvastatin was 0\u00b729\u00b10\u00b704 1 kg\u22121<\/jats:sup> while the total body clearance was 0\u00b733\u00b10\u00b705 1 h\u22121<\/jats:sup> kg\u22121<\/jats:sup>. The administered radioactivity was excreted predominantly in feces, with the renal pathway accounting for 28\u00b14 per cent of the oral dose and 32\u00b13 per cent of the intravenous dose. In pregnant rabbits on a multiple oral dosing regimen, 1 mg kg\u22121<\/jats:sup> day\u22121<\/jats:sup> beginning day 6 post\u2010conception (p.c.), steady\u2010state concentrations in maternal blood and tissues were achieved within 5 days. The concentrations in the reproductive organs were c<\/jats:italic>. 25\u201350 per cent of that in maternal blood while those in the kidneys and liver were considerably higher. In contrast, radioactivity levels in the fetuses and amniotic fluid decreased significantly during repeated drug administration. The fetus: placenta and amniotic fluid: placenta concentration ratios declined from 0\u00b792 and 0\u00b797, respectively, on day 10 p.c. to 0\u00b710 and 0\u00b704, respectively, on day 18 p.c., indicating a limited transfer of fluvastatin and\/or its metabolite(s) across the placenta at the later stage of pregnancy. After cessation of dosing, radioactivity levels in all tissues and fluids showed a progressive and nearly parallel, decline, suggesting no tissue retention of the drug.<\/jats:p>","DOI":"10.1002\/bdd.2510130407","type":"journal-article","created":{"date-parts":[[2006,10,14]],"date-time":"2006-10-14T13:02:00Z","timestamp":1160830920000},"page":"285-294","source":"Crossref","is-referenced-by-count":9,"title":["Absorption and disposition of fluvastatin, an inhibitor of HMG\u2010CoA reductase, in the rabbit"],"prefix":"10.1002","volume":"13","author":[{"given":"F. L. S.","family":"Tse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Labbadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,2,7]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.261.24.3582"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/oxfordjournals.bmb.a072439","article-title":"Treatment of hyperlipidaemia","volume":"46","author":"Illingworth D. R.","year":"1990","journal-title":"Brit. Med. Bull."},{"key":"e_1_2_1_4_2","unstructured":"R. G.Engstrom D. B.Weinstein F. G.Kathawala T.Scallen J. B.Eskesen M. L.Rucker R.MiserendinoandJ.Babiak Hypolipoproteinemic activity of XU 62\u2010320 a potent competitive inhibitor of HMG\u2010CoA reductase Eighth International Symposium on Atherosclerosis Rome October 9\u201313 1988 p.230."},{"key":"e_1_2_1_5_2","unstructured":"F. G.Kathawala T.Scallen R. G.Engstrom D. B.Weinstein H.Schuster R.Stabler J.Kratunis J. R.Wareing W. F.Jewell L.WidlerandS.Wattanasin XU 62\u2013320 an HMG\u2010CoA reductase inhibitor more potent than compactin and lovastatin Eighth International Symposium on Atherosclerosis Rome October 9\u201313 1988 p.445."},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510110606"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600680845"},{"key":"e_1_2_1_8_2","first-page":"29","volume-title":"Fetal Pharmacology","author":"Levy G.","year":"1973"}],"container-title":["Biopharmaceutics & Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdd.2510130407","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.2510130407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T13:28:16Z","timestamp":1698154096000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.2510130407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,5]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1992,5]]}},"alternative-id":["10.1002\/bdd.2510130407"],"URL":"https:\/\/doi.org\/10.1002\/bdd.2510130407","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,5]]}}}